Back to Search
Start Over
Multiple myeloma treatment strategies with novel agents in 2011: A European perspective
- Source :
- Digital.CSIC. Repositorio Institucional del CSIC, instname, Ludwig, H, Beksac, M, Bladé, J, Cavenagh, J, Cavo, M, Delforge, M, Dimopoulos, M, Drach, J, Einsele, H, Facon, T, Goldschmidt, H, Harousseau, J-L, Hess, U, Kropff, M, Leal da Costa, F, Louw, V, Magen-Nativ, H, Mendeleeva, L, Nahi, H, Plesner, T, San-Miguel, J, Sonneveld, P, Udvardy, M, Sondergeld, P & Palumbo, A 2011, ' Multiple Myeloma Treatment Strategies with Novel Agents in 2011: A European Perspective ', Oncologist, vol. 16, no. 4, pp. 388-403 . https://doi.org/10.1634/theoncologist.2010-0386, Oncologist, 16(4), 388-403. AlphaMed Press
- Publication Year :
- 2011
- Publisher :
- AlphaMed Press, 2011.
-
Abstract
- The arrival of the novel agents thalidomide, bortezomib, and lenalidomide has significantly changed our approach to the management of multiple myeloma and, importantly, patient outcomes have improved. These agents have been investigated intensively in different treatment settings, providing us with data to make evidence-based decisions regarding the optimal management of patients. This review is an update to a previous summary of European treatment practices that examines new data that have been published or presented at congresses up to the end of 2010 and assesses their impact on treatment practices. © AlphaMed Press.<br />Advisory Board meeting supported by Janssen Pharmaceutical Companies of Johnson and Johnson in Europe, Middle East, and Africa (EMEA). Unrestricted educational grant provided by Janssen Pharmaceutical Companies of Johnson and Johnson in the EMEA to assist with editorial support.
- Subjects :
- Cancer Research
medicine.medical_specialty
Evidence-based practice
Comorbidity
Disease-Free Survival
law.invention
Bortezomib
Randomized controlled trial
law
Academia-Pharma Intersect
Antineoplastic Combined Chemotherapy Protocols
medicine
Autologous transplantation
Humans
Intensive care medicine
Lenalidomide
Multiple myeloma
business.industry
Perspective (graphical)
Age Factors
novel agents
Congresses as Topic
medicine.disease
Boronic Acids
Thalidomide
Europe
Treatment Outcome
Oncology
Evidence-Based Practice
Pyrazines
Immunology
business
Multiple Myeloma
medicine.drug
Stem Cell Transplantation
Subjects
Details
- ISSN :
- 10837159
- Database :
- OpenAIRE
- Journal :
- Digital.CSIC. Repositorio Institucional del CSIC, instname, Ludwig, H, Beksac, M, Bladé, J, Cavenagh, J, Cavo, M, Delforge, M, Dimopoulos, M, Drach, J, Einsele, H, Facon, T, Goldschmidt, H, Harousseau, J-L, Hess, U, Kropff, M, Leal da Costa, F, Louw, V, Magen-Nativ, H, Mendeleeva, L, Nahi, H, Plesner, T, San-Miguel, J, Sonneveld, P, Udvardy, M, Sondergeld, P & Palumbo, A 2011, ' Multiple Myeloma Treatment Strategies with Novel Agents in 2011: A European Perspective ', Oncologist, vol. 16, no. 4, pp. 388-403 . https://doi.org/10.1634/theoncologist.2010-0386, Oncologist, 16(4), 388-403. AlphaMed Press
- Accession number :
- edsair.doi.dedup.....d1aa0ac783e8997d90ae575262d548e0